ReviewNeuroscience research2017
Valley of death: A proposal to build a "translational bridge" for the next generation.
Review in Neuroscience research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Systematic review and meta-analysis of the antidepressant-like effects of ginsenosides in animal models: comparative behavioral profiles and exploratory dose-stratified analysis.Frontiers in pharmacology · 2026Pooled it
- Comparative insights into insula structure and function.Nature neuroscience · 2026Review
- The innovation disconnect: Can artificial intelligence finally align academic discovery with industry needs?Indian journal of pharmacology · 2026Article
- A new module in the drug development process: preclinical multi-center randomized controlled trial of R-ketamine on alcohol relapse.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Article
- Translational science at the undergraduate level: awakening talents to overcome the valley of death - case report.The journal of venomous animals and toxins including tropical diseases · 2025Article
- Implantable Passive Sensors for Biomedical Applications.Sensors (Basel, Switzerland) · 2024Review
- Article
- Negative equity - the value of reporting negative results.Disease models & mechanisms · 2024Article
- Drug Development for New Psychiatric Drug Therapies.Advances in neurobiology · 2023Article
- Optimized Administration of the MACS chemical neuroscience · 2022Article
- Clinical and Preclinical Evidence for MNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Article
- A "Failed" Assay Development for the Discovery of Rescuing Small Molecules from the Radiation Damage.SLAS discovery : advancing life sciences R & D · 2021Article
- Advances in high-resolution mass spectrometry applied to pharmaceuticals in 2020: A whole new age of information.Analytical science advances · 2021Review
- Single-Target Versus Multi-Target Drugs Versus Combinations of Drugs With Multiple Targets: Preclinical and Clinical Evidence for the Treatment or Prevention of Epilepsy.Frontiers in pharmacology · 2021Review
- Drug/Lead Compound Hydroxymethylation as a Simple Approach to Enhance Pharmacodynamic and Pharmacokinetic Properties.Frontiers in chemistry · 2021Review
- Pharmacological Optimization for Successful Traumatic Brain Injury Drug Development.Journal of neurotrauma · 2020Review
- From Genetics to Precision Therapy: Finding a Path through the Scientific Valley of Death.American journal of respiratory cell and molecular biology · 2019Article
- Opportunities in posthemorrhagic hydrocephalus research: outcomes of the Hydrocephalus Association Posthemorrhagic Hydrocephalus Workshop.Fluids and barriers of the CNS · 2018Review
- Translational Geroscience: From invertebrate models to companion animal and human interventions.Translational medicine of aging · 2018Article
- The price of progress: Funding and financing Alzheimer's disease drug development.Alzheimer's & dementia (New York, N. Y.) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
Abstract
There is a great need for novel drug discovery for major mental illnesses, but multiple levels of challenges exist in both academia and industry, spanning from scientific understanding and institutional infrastructure to business risk and feasibility. The "valley of death," the large gap between basic scientific research and translation to novel therapeutics, underscores the need to restructure education and academic research to cultivate the fertile interface between academia and industry. In this opinion piece, we propose strategies to educate young trainees in the process of drug discovery and development, and prepare them for careers across this spectrum. In addition, we describe a research framework that considers the disease trajectory and underlying biology of mental disorders, which will help to address the core pathophysiology in novel treatments, and may even allow early detection and intervention. We hope that these changes will increase understanding among academia, industry, and government, which will ultimately improve the diagnosis, prognosis and treatment of mental disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.